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Abstract This study was aimed at the assessment of
incidence of malignancies in type 2 diabetic patients trea-
ted with different sulphonylureas. A matched case–control
study was performed. Cases were 195 diabetic patients
aged 69.0 ± 9.2 years who had an incident malignancy.
Controls were 195 diabetic patients, unaffected by cancer,
who were matched with the corresponding case for age,
sex, duration of diabetes, BMI, HbA1c, comorbidity,
smoking and alcohol abuse. Exposure to hypoglycaemic
drugs during the 10 years preceding the event (or matching
index date) was assessed. After adjusting for concomitant
therapies, exposure to metformin and gliclazide for more
than 36 months was associated with a significant reduction
in the risk of cancer (adj. ORs with 95% CI: 0.28 (0.13–
0.57), p \ 0.001, and 0.40 (0.21–0.57), p = 0.004,
respectively). Conversely, use of glibenclamide for at least
36 months was associated with increased incidence of
malignancies (adj. OR 2.62 (1.26–5.42); p = 0.009).
Treatment with insulin, thiazolidinediones, or acarbose,
was not associated with significant differences in the
incidence of cancer. Long-term treatments with individual
sulphonylureas could have differential effects on the risk of
cancer. In particular, the possible protective effect of
gliclazide, as well as the risk associated with glibencla-
mide, deserves further investigation.
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Introduction
A recent retrospective study has shown that treatment with
sulphonylureas could be associated with increased cancer-
related mortality, without exploring possible differences
among individual sulphonylureas [1]. A preliminary epi-
demiological report raised the hypothesis that glibenclamide
could be associated with a higher mortality for malignancies
in comparison with gliclazide [2]. This is in line with
experimental data, suggesting differential effects of sul-
phonylureas on carcinogenesis [3]. The present case–control
study was designed to assess the association of malignan-
cies with the use of glibenclamide, gliclazide, and other
secretagogues.
Subjects, materials and methods
Data collection
This study was performed on a consecutive series of 1,945
diabetic outpatients, living within the region of Tuscany,
and referring for the first time to the Diabetes Outpatient
Clinic of the Geriatric Unit of the University of Florence
between January 1, 1998, and December 31, 2004.
Demographic and clinical data, including history of hy-
poglycaemic medication, self-reported smoking habits and
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alcohol intake, were collected, as part of the routine clin-
ical assessment. Alcohol consumption of more than two
drinks/day was used as a cut-off to define alcohol abuse. At
first visit, following a standard procedure of the Clinic, all
patients underwent a physical examination, including
measurement of weight, height, and blood pressure, fol-
lowing WHO recommendations [4, 5]. A fasting blood
sample was used for determining HbA1c (HPLC, Menarini-
Diagnostici, Italy; UNL 6.2%) creatinine, total choles-
terol, HDL-cholesterol, and triglyceride (all measured
with an automated method: Aeroset, Abbott Laboratories).
Comorbidity was assessed through the calculation of
Charlson’s comorbidity score (CCS), which includes dia-
betes and its complications, cardiovascular disease, chronic
skin ulcers, renal insufficiency, liver diseases, chronic
obstructive pulmonary disease, malignancies, arthritis/
arthrosis, HIV-infections [6].
Identification of case patients and controls
Incident cases of cancer from enrolment up to December
31, 2005, were identified through queries to registers of
hospital admissions and causes of death. The event was
considered as the first of either hospital admission or death
with the international classification of diseases (ICD)-9
codes 140–209. Information on hospital admission was
obtained through the Regional Hospital Discharge system,
which contains ICD codes of current diagnoses. Deaths
from cancer were obtained from the Mortality Registry of
Tuscany. Patients with known malignancies at first visit
(n = 26) were excluded. Case finding was therefore per-
formed on 1,919 patients (827 and 1,092 women and men,
respectively), aged 63.9 ± 12.8 years, with a mean dura-
tion of diabetes of 10.7 ± 10.5 years.
Incident cases of cancer were compared with an equal
number of controls selected from the same cohort. For each
case, the first subsequent patient within the same series, of
the same sex, age (±2 years), duration of diabetes
(±2 years), HbA1c (±1%), BMI (±2 kg/m2), comorbidity
score (CCS ± 1 point), smoking status (current/former/
never smoker), and alcohol abuse (yes/no), was taken as
control.
Exposure of hypoglycaemic drugs
Exposure to hypoglycaemic drugs during the 10 years
preceding the event, in cases, and before the matching
index dates, in controls, was assessed. Such assessment was
not performed in the rest of the cohort. Drug exposure was
obtained from clinical records of the Outpatient Clinic.
These records contain self-reported history of hypogly-
caemic treatment before the first contact with the Clinic,
and all drug prescriptions during follow-up. If the last
available visit occurred more than 3 months before the
event (or the matching index date), a telephone contact
with the patients or their relatives was attempted, in order
to collect further information on subsequent drug use. If no
such information was obtained, the patient was assumed to
have continued the last available hypoglycaemic therapy.
Patients were categorized according to their exposure to
each agent (any exposure, or treatment for at least 12 or
36 months). Exposure to different combinations of hypo-
glycaemic treatments were also assessed.
Statistical analysis
Unpaired Student’s t test and Mann–Whitney test were
used to compare continuous variables whenever appro-
priate. Chi-square test was used for between-group
comparisons of categorical variables, computing odds
ratios (ORs) with 95% confidence interval (CI). Exposure
to each drug was compared to lack of exposure to the
same drug. Conditional logistic regression was used for
multivariate analysis, in order to adjust for concomitant
hypoglycaemic treatments; no other adjustments were
made, as cases and controls had been carefully matched
for the other potential confounders, as described above.
Considering that, due to the availability of fixed-dose
combinations, glibenclamide is more often associated to
biguanides than other secretagogues [7], additional anal-
yses including exposure to combined secretagogues-
biguanide therapy among confounders were performed in
order to explore interactions. On the other hand, other
combinations of hypoglycaemic drugs, less frequent in the
sample, were not analysed separately because of the
insufficient sample size. Furthermore, although a possible
effect on the incidence of cancer of ACE-inhibitors and
calcium channel blockers [8] was not confirmed by other
studies [9, 10], a further multivariate analysis on 36-
month exposure to hypoglycaemic drugs was performed
including among covariates’ treatment with those two
categories of antihypertensive medications at baseline. All
analyses were carried out with SPSS 12.0.1 statistical
package, and a p \ 0.05 was considered statistically
significant.
Results
Mean duration of follow-up in the reference cohort was
6.5 ± 3.8 years, during which 195 new cases of cancer
were identified, with an incidence of 2.49/100 per-
sons 9 year. The most frequent malignancies observed
were of gastrointestinal tract (N = 48; of those, 4
oesophageal, 15 gastric, 21 intestinal), female genital tract/
mammary glands (N = 27; of those, 6 uterine, 7 cervical,
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and 12 mammary glands), male genital tract (N = 26; of
those, 18 prostate), pancreas (N = 22), and lung (N = 18).
The characteristics of cases and controls, at the time of
their first visit at the Outpatient Clinic, are summarized in
Table 1. No significant difference was observed between
the two groups, except for lower total cholesterol levels in
cases.
Follow-up obtained from clinical records was incom-
plete in 28 (14.4%) cases and 31 (15.9%) controls.
Information about treatment was collected through a tele-
phone contact in most of those subjects. In eight (4.1%)
cases and six (3.1%) controls, hypoglycaemic treatment
after the last contact with the clinic could not be assessed;
those patients were assumed to have continued the last
available hypoglycaemic therapy.
When considering hypoglycaemic treatments during the
previous 10 years, a lower proportion of cases had been
exposed to metformin for more than 12 or 36 months in
comparison with controls; furthermore, any exposure to
gliclazide was more frequent in controls than in cases
(Table 2).
Logistic regression model
Insulin secretagogues were often associated with bigua-
nides. Among patients treated with insulin secretagogues
for at least 36 months, 89.6, 80.0, 22.2, and 11.3% on
glibenclamide, repaglinide, glimepiride, and gliclazide
were receiving also a biguanide for the entire duration of
secretagogue treatment; all patients treated with chlor-
propamide were on combined therapy. A multivariate
analysis was therefore performed in order to assess the
effect of each treatment after adjusting for concomitant
hypoglycaemic medications.
At multivariate analysis, treatment for at least
36 months with insulin sensitizers, insulin secretagogues,
insulin, or acarbose, was not associated with significant
differences in the risk of malignancies (adj. ORs 0.72
(0.43–1.19), 0.85 (0.52–1.39), 1.01(0.64–1.59), and 0.65
(0.11–3.95), respectively). The results of an alternative
model of multivariate analysis, in which metformin and
thiazolidinediones were considered separately, and gli-
benclamide and gliclazide were included as individual
drugs, are summarized in Fig. 1. After adjusting for other
hypoglycaemic treatments, exposure to metformin for more
than 12 or 36 months was associated with a significant
reduction of risk (both p \ 0.001), while no effect was
observed for thiazolidinediones, insulin or acarbose.
Among insulin secretagogues, 12- and 36-month exposure
to glibenclamide was associated with an increased risk of
cancer (p = 0.01 and 0.009, respectively), while gliclazide
was associated with a reduction of risk (p = 0.004 and
0.001 for 12-and 36-month exposure, respectively). Similar
results were obtained when the exposure for more than 12
and 36 months to the combination of insulin secretagogues
and biguanides was added to the model (data not shown).
A further analysis was performed, including treatment
with calcium channel blockers and ACE-inhibitors at
baseline among covariates, exploring 36-month exposure
to hypoglycaemic agents as a possible determinant of
incident cancer; the results were not different from those
reported above (data not shown).
Table 1 Baseline
Characteristics of the
sample enrolled
BMI body mass index, BP blood
pressure
Controls Case patients p
Number (Women, %) 195 (41.0) 195 (41.0) –
Age (years) 69.0 ± 9.2 69.5 ± 9.1 0.63
Duration of diabetes (years) 9.3 ± 10.4 9.3 ± 10.4 0.99
HbA1c (%) 7.7 ± 1.7 7.7 ± 1.8 0.70
BMI (kg/m2) 27.5 ± 4.5 27.5 ± 4.9 0.92
Charlson comorbidity score 2.4 ± 1.5 2.4 ± 1.5 0.74
Total cholesterol (mg/dl) 203.2 ± 52.1 192.0 ± 53.8 0.04
HDL cholesterol (mg/dl) 47.1 ± 15.0 45.4 ± 13.2 0.27
Triglycerides (mg/dl) 157.0 [106.0; 218.0] 140.0 [103.0; 196.0] 0.17
Systolic BP (mmHg) 145.0 ± 19.7 143.0 ± 19.8 0.35
Diastolic BP (mmHg) 80.4 ± 10.4 79.8 ± 11.2 0.57
Antihypertensive drugs (%) 55.4 54.4 0.84
ACE-inhibitors (%) 33.2 30.1 0.57
Calcium-channel blockers (%) 9.1 10.2 0.77
Statins (%) 21.0 21.5 0.90
Antiaggregants (%) 41.5 39.0 0.61
Alcohol abuse (%) 14.4 15.9 0.67
Current smokers (%) 17.9 19.5 0.70
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Among cases who had received glibenclamide for more
than 36 months (N = 68), the most frequent forms of
cancer were of gastrointestinal (N = 18), female genital
tract/mammary glands (N = 13), male genital tract
(N = 11), pulmonary (N = 7), and pancreatic (N = 4).
After adjustment for biguanide therapy, HRs of exposure to
glibenclamide for more than 36 months were 2.45 (0.86–
6.94) (p = 0.09), 3.47 (0.95–12.70) (p = 0.06), and 2.12
(0.57–7.92) (p = 0.26) for malignancies of gastrointestinal
tract, female genital tract-mammary glands, and male
genital tract, respectively. Among cases who had received
gliclazide for more than 36 months (N = 19), the most
frequent forms of cancer were of gastrointestinal (N = 5),
female genital tract/mammary glands (N = 4), and pan-
creatic (N = 3).
Discussion
The present study does not support the hypothesis that a
class effect of sulphonylureas determined an increased risk
of cancer, as suggested by a previous study [1]. The design
Table 2 Exposure to hypoglycaemic treatments in cases and matched controls
Any time At least 12 months At least 36 months
Controls Case patients Controls Case patients Controls Case patients
Insulin secretagogues (n, %) 134 (69.7) 128 (65.6) 124 (63.6) 107 (54.9) 109 (55.9) 92 (47.2)
Glibenclamide 76 (39.0) 82 (42.1) 71 (36.4) 76 (39.0) 66 (33.8) 68 (34.9)
Glimepiride 22 (11.3) 17 (8.7) 3 (1.5) 6 (3.1) 3 (1.5) 6 (3.1)
Gliclazide 51 (26.2) 29 (14.9)** 47 (24.1) 25 (13.3)** 34 (17.4) 19 (9.7)*
Chlorpropamide 9 (4.6) 6 (3.1) 9 (4.6) 5 (2.6) 9 (4.6) 5 (2.6)
Tolbutamide 1 (0.5) 0.0 1 (0.5) 0.0 1 (0.5) 0.0
Gliquidione 4 (2.1) 2 (1.0) 3 (1.5) 1 (0.5) 1 (0.5) 0.0
Glipizide 0.0 1 (0.5) 0.0 1 (0.5) 0.0 1 (0.5)
Repaglinide 16 (8.2) 18 (9.2) 8 (4.1) 7 (3.6) 3 (1.5) 2 (1.0)
Insulin sensitizers (n, %) 120 (62.1) 114 (58.5) 110 (56.4) 90 (46.2)* 88 (45.6) 69 (35.4)*
Metformin 120 (61.5) 113 (57.9) 110 (56.4) 88 (45.6)* 88 (45.6) 69 (35.4)*
Fenformin 4 (2.1) 7 (3.6) 2 (1.0) 6 (3.1) 1 (0.5) 4 (2.1)
Glitazones 2 (1.0) 4 (2.1) 2 (1.0) 3 (1.5) 2 (1.0) 0 (0.0)
Acarbose (n, %) 8 (4.1) 7 (3.6) 5 (2.6) 7 (3.6) 3 (1.5) 2 (1.0)
Insulin (n, %) 74 (37.9) 92 (47.2) 66 (33.8) 66 (33.8) 55 (28.2) 48 (24.7)
Data are expressed as %. * p \ 0.05; ** p \ 0.01
Fig. 1 Adjusted ORs, with 95%
CI, for malignancies of
exposure to different
hypoglycaemic drugs (as
compared to no exposure to the
same drug) in a logistic
regression model. Data are
presented on a logarithmic scale
(SUs sulphonylureas)
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of that study, showing a higher cancer-related mortality in
diabetic patients treated with sulphonylureas in comparison
with those receiving metformin, did not allow to discrim-
inate whether this difference was due to a risk induced by
sulphonylureas, or to a protective effect of metformin [11],
or both; similar considerations should be made with respect
to another study, which associated metformin with reduced
risk of cancer [11]. With respect to sulphonylureas, avail-
able data analysed the effect on incidence of malignancies
and cancer-related mortality of the class as a whole [1, 11].
We have observed some differences in mortality among
individual insulin secretagogues [2, 12], which could be
due, at least partly, to differences in cancer-related mor-
tality [2], which are consistent with the results of the
present study. This is the first report of a reduction of
the risk for cancer in patients treated with gliclazide. The
mechanisms underlying this possible protective effect are
speculative; however, they could include the well-known
anti-oxidant effects of this drug, which has been shown to
prevent DNA damage in vitro [3].
We also observed an association between treatment with
glibenclamide and the incidence of malignancies. This
association was evident only at multivariate analysis; in
fact, the concomitant protective effect of metformin, which
was co-administered with glibenclamide in most cases,
masked the possible increase of risk associated with this
sulfonylurea. No increase of risk is observed with insulin
secretagogues different from glibenclamide, suggesting a
drug-specific effect, which deserves further investigation.
The previously reported association of insulin therapy
with increased cancer-related mortality [1] was not con-
firmed by our data. It should be considered that the
described association of insulin with cancer-related mor-
tality could have been determined by some unexplored
prescription bias: patients receiving a prescription of
insulin are likely to have a more ‘‘severe’’ form of type 2
diabetes, a greater duration of diabetes, or comorbidities
contraindicating treatment with oral agents. In fact, the
issue of an effect of hypoglycaemic treatments on the risk
of cancer has been raised by observational studies, which
can be biased by uncontrolled confounders, such as those
cited above. In the present study, the match of cases and
controls for comorbidity could have eliminated the asso-
ciation of malignancies with insulin treatment. Prolonged
exposure to metformin was associated with a reduction of
the incidence of malignancies. This is consistent with a
previous case-control study [7] showing a protective effect
of metformin. The use of thiazolidinediones, which have
been recently associated with increased cancer risk in a
smaller cross-sectional study [13], was not wide enough to
allow any specific statistical analysis. Interestingly, a
recent meta-analysis did not show any increase of incident
malignancies with rosiglitazone [14].
The main weakness of this study is the fact that infor-
mation on treatments was obtained partly through
prescriptions contained in patients’ clinical records, and
partly through self-reported drug history. A gap between
prescribed and actual therapy, which could be different
with individual agents, could bias the results. Furthermore,
it is possible that self-reporting was inaccurate in some
cases. However, these biases could hardly explain the
differences in risk associated with similar treatments, such
as glibenclamide and other insulin secretagogues. It should
also be considered that a delay in the identification of
incident malignancies could have occurred in some cases.
On the other hand, some strengths of this case–control
study should also be recognized. The use of a clinical series
of patients allowed a very exact match between cases and
controls, thus eliminating some confounders usually
affecting observational studies, such as body mass index,
duration of diabetes, degree of glycaemic control, comor-
bidities, and smoking and drinking habits. Furthermore,
exposure to hypoglycaemic agents was assessed for a time
span consistent with the aims of the study.
The limited size of the sample does not allow drawing
any definitive conclusion on the association of hypogly-
caemic treatments with site-specific forms of cancer. Such
information can only be obtained through the analysis of
much larger cohorts. On the other hand, it is practically
difficult to obtain a detailed clinical characterization of a
very large cohort of individuals, making such a study dif-
ficult to realize.
Despite the accurate matching of cases and controls, and
the adjustment for identified confounders, a prescription
bias is inevitable in observational studies on the long-term
effects of drug treatments. In fact, it is possible that patients
receiving different drugs, although of the same class, are
different for some features which were not taken into
account in the present study. Results of randomized clinical
trials, if available, would be free of this bias; however, the
few published long-term studies on sulphonylureas [15, 16]
were performed in newly-diagnosed patients, in an age
range in which the incidence of malignancies is relatively
low. In particular, the UK Prospective Diabetes Study did
not report detailed data on incident malignancies [14]. On
the other hand, newly-diagnosed cases of cancer in the
ADOPT study [15] could be retrieved from the GSK-
website, which reports all adverse events. Based on those
data, the incidence of cancer was 1.5, 1.1, and 1.1 cases/
100 patient 9 years in the glibenclamide, metformin, and
rosiglitazone groups, respectively; the difference did not
reach statistical significance due to the relatively small
number of cases. Further, ongoing trials [17, 18], could add
some relevant information.
In conclusion, glibenclamide, different from other
stimulators of insulin secretion, could be associated with
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increased risk of cancer, while gliclazide could have a
protective effect. Further data should be collected, in larger
samples of patients, in order to elucidate the actual risk
profile of these insulin secretagogues.
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